🇺🇸 FDA

Company profile · Sponsor

Inhibikase

Inhibikase Therapeutics

IKT · NYSE biotech WILMINGTON, DE, USA
Pipeline
4
Drugs
0
Patents
8

Quick answer

Inhibikase (IKT) is a biotech company. headquartered in WILMINGTON, DE, USA. listed on NYSE. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker IKT
Exchange NYSE
Company type biotech
Headquarters WILMINGTON, DE, USA
SEC CIK 0001750149

Pipeline (4)

Search pipeline →

  1. IKT-001

    Inhibikase

    Pulmonary Arterial Hypertension

    phase 3 small molecule active

    1 trial

  2. IkT-001Pro, Placebo to match 100 mg IKT-001 tablets

    Inhibikase

    Pulmonary Arterial Hypertension

    phase 3 small molecule active

    1 trial

  3. IkT-001Pro

    Inhibikase

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule terminated

    1 trial

  4. Imatinib Mesylate

    Inhibikase

    CML

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 11725005

    Compositions and methods for inhibiting kinases

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11407747

    Compositions and methods for inhibiting kinases

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10906896

    Compositions and methods for inhibiting kinases

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10344027

    Compositions and methods for inhibiting kinases

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10316031

    Compositions and methods for inhibiting kinases

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10118923

    Compositions and methods for inhibiting kinases

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9907796

    Methods of treating tumoral diseases, or bacterial or viral infections

    Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9828370

    Compositions and methods for inhibiting kinases

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Inhibikase?

Inhibikase (IKT) is a biotech company. headquartered in WILMINGTON, DE, USA. listed on NYSE. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Inhibikase sponsor?

We track 4 ClinicalTrials.gov-linked programs for Inhibikase, including IKT-001 and 3 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Inhibikase company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.